Skip to main content
| News

Bachem builds its largest production building

11.11.2021

Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of peptides and oligonucleotides will initially create up to 150 new skilled jobs with this. This will strengthen the position of Bubendorf, located in the Basel Area, as a center of excellence.

Bachem Bubendorf
Bachem is specializing in the manufacture of peptides and oligonucleotides (img: Bachem)

Bachem has started construction of the world’s most high-tech production building for peptides and oligonucleotides at its location in Bubendorf in the canton of Basel-Landschaft. The foundation stone was laid on Thursday. According to a press release, the building should expand the production capacities for these complex molecules by 2024 at the latest. These substances are used in medicinal products used to treat various diseases.

In a first phase, up to 150 positions, most of which will be highly skilled, are to be created there. The listed company has invested over 150 million Swiss francs and created 400 new jobs at its two sites in Bubendorf and Vionnaz (in the canton of Valais) over the past five years. The new production building will now strengthen the Bubendorf site’s position as a “leading center of excellence for the manufacture of complex pharmaceutical active ingredients” according to the press release. Additionally, it represents a clear commitment to Switzerland and Basel Area as a location.

Since global demand for these molecules is constantly increasing, Bachem is already looking for a third production site in Switzerland. The land reserves at the Bubendorf site will be exhausted in the medium term.

The company celebrated its 50th anniversary this year. CEO Thomas Meier is delighted that the foundation stone was laid on Swiss National Future Day, which is a day for young people to learn about working in a company. Meier adds: “Our success is founded on our ability to invest into our company efficiently and with foresight, but also on the ability to excite new generations for the impact chemistry and the natural sciences can have.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

South Korean pharma firms show interest in the Basel Area
Basel Area Business & Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.